Clinical trials: fludarabine phosphate, completed
Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients
This study investigates an innovative treatment for recurrent ovarian cancer exploiting ex vivo-generated allogeneic natural killer (NK) cells with or without preceding non-myeloablative conditioning chemotherapy.
- Conditions
- Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- INTRO (NCT03539406)
- Testing
- UCB-NK cells, Chemotherapy
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Radboud University Medical Center
Leukemia, Lymphoma
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
The purpose of this study is: 1. To establish the maximally tolerated dose (MTD) of intravenous busulfan (Busulfan®) in combination with fludarabine as conditioning regimen for transplantation with in-vivo T-cell depletion. 2.
- Conditions
- Leukemia, Lymphoma, Myeloma
- Trial name
- NCT00943319
- Testing
- Busulfan, Fludarabine, Campath
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Chronic Lymphocytic Leukemia (CLL)
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a…
- Trial name
- CRISTALLO (NCT04285567)
- Testing
- Obinutuzumab, Venetoclax, Fludarabine
- Where
- 40 sites in United States, Australia and 3 more
- Volunteers
- 166 people
- Sponsor
- Hoffmann-La Roche
GVHD, AML
Haplo Peripheral Blood Sct In GVHD Prevention
This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative…
- Conditions
- GVHD, AML, ALL, MDS
- Trial name
- NCT04473911
- Testing
- FLUDARABINE, CYCLOPHOSPHAMIDE, TBI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Zachariah Michael DeFilipp
Cerebral Adrenoleukodystrophy (CALD)
A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
The purpose of this study is to evaluate the efficacy and safety of Lenti-D Drug Product (also known as elivaldogene autotemcel or Skysona, hereafter referred to as eli-cel) after myeloablative conditioning with busulfan and…
- Trial name
- NCT03852498
- Testing
- Lenti-D
- Where
- 8 sites in United States, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Genetix Biotherapeutics Inc.
Bone Marrow Failure, Osteopetrosis
Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
This study proposes the use of a reduced intensity chemotherapy/radiation therapy regimen followed by stem cell transplantation, as compared to standard ablative chemotherapy regimens associated with stem cell transplantation, in…
- Conditions
- Bone Marrow Failure, Osteopetrosis, Fanconi Anemia, Severe Combined Immunodeficiency
- Trial name
- NCT01019876
- Testing
- Fludarabine, Cyclophosphamide, Busulfan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Columbia University
Acute Myeloid Leukaemia
Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)
This is a multicenter, multinational, non-randomized, non-controlled open-label phase II trial to evaluate the safety and efficacy of treosulfan in a combination regimen with fludarabine as conditioning therapy prior to…
- Trial name
- NCT01063660
- Testing
- Treosulfan
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- medac GmbH
Leukemia, Lymphoid, Leukemia, Myeloid
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant.
- Conditions
- Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes, Myelofibrosis
- Trial name
- FluBuATG (NCT02916979)
- Testing
- Fludarabine, Busulfan, Rabbit ATG
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Metastatic Melanoma
Vemurafenib and TIL Therapy for Metastatic Melanoma
Background: Adoptive T cell therapy with tumor infiltrating lymphocytes (TILs) has been reported to induce durable clinical responses in patients with metastatic melanoma.
- Trial name
- NCT02354690
- Testing
- Vemurafenib, Lymphodepleting chemotherapy, TIL infusion
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Inge Marie Svane
Immunosuppression, Leukemia
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor s T cells (a type of lymphocyte, or white blood cell) have been removed and then added back.
- Trial name
- NCT00353860
- Testing
- SOLEX 300i Stem Cell Selection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Castrate-Resistant Prostate Cancer
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
PD1-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer
- Trial name
- NCT04768608
- Testing
- PD1-PSMA-CART cells
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhejiang University
Thalassemia Major
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
The only curative therapy for thalassemia major remains the replacement of the defective erythropoiesis by allogeneic hematopoietic stem cell transplantation(allo-HSCT).
- Trial name
- NCT04009525
- Testing
- Busulfan, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 823 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
B-cell Lymphoma
PD1-CD19-CART in Patients With r/r B-cell Lymphoma
This is an open label, single-site, dose-escalation study in up to 25 participants with relapse/refractory B-NHL. This study aims to evaluate the safety and efficacy of the treatment with PD1-CD19-CART.
- Trial name
- NCT04213469
- Testing
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Bioray Laboratories
Leukemia, Lymphoma
Bryostatin + Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00005580
- Testing
- bryostatin 1, fludarabine phosphate
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Virginia Commonwealth University
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Multiple Myeloma, Myeloma
FT576 in Subjects With Multiple Myeloma
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
- Trial name
- NCT05182073
- Testing
- FT576 (Allogenic CAR NK cells with BCMA expression), Cyclophosphamide, Fludarabine
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fate Therapeutics
Aplastic Anemia
Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia
This study is for patients with Severe Aplastic Anemia (SAA). A stem cell transplant from a genetically matched sibling donor can help or cure this disease in 85 to 100 percent of patients.
- Trial name
- AACD34 (NCT00186797)
- Testing
- Allogeneic stem cell transplant, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia
Assessment of SARS-CoV2 (mRNA and adenovirus-based vaccines) and Conjugated Pneumococcal (PCV13) in Patients with Chronic Lymphocytic Leukemia
- Trial name
- NCT05007860
- Testing
- PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
High Risk Myeloid Malignancies, Cord Blood Transplant
US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality.
- Trial name
- NCT04990323
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- ExCellThera inc.
Hematologic Malignancies
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies
Primary: Define the maximal tolerated dose (MTD) of VNP40401M when given with hematopoietic cell transplantation (HCT) Secondary: Describe the change in pharmacokinetic (PK) parameters with increasing doses of drug.
- Trial name
- NCT00521859
- Testing
- Cloretazine, Fludarabine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center